Beam Therapeutics Inc.
BEAMBeam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 4, 2026
7wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
BEAM-101
Sickle Cell Disease
BEAM-201
Lymphoblastic Lymphoma
BEAM-301: Single dose of BEAM-301 administered by IV
Glycogen Storage Disease Type Ia
BEAM-302
Alpha 1-Antitrypsin Deficiency
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BEAM-101 | Phase 2 | Sickle Cell Disease | - | - |
BEAM-201 | Phase 2 | Lymphoblastic Lymphoma | - | - |
BEAM-301: Single dose of BEAM-301 administered by IV | Phase 2 | Glycogen Storage Disease Type Ia | - | - |
BEAM-302 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Sickle Cell Disease
1 drug in this indication
Lymphoblastic Lymphoma
1 drug in this indication
Glycogen Storage Disease Type Ia
1 drug in this indication
Alpha 1-Antitrypsin Deficiency
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)